OSD
Myeloma is a very individual cancer, both in terms of what symptoms and complications patients can have and in the way they respond to treatment. Improvements made to treatment over the last decade have meant that survival rates are increasing, however there is still no cure and there remains a significant need for more efficacious and tolerable therapies. To this end, Oncopeptides needed an experienced partner to help take its promising molecule from the discovery phase through to clinical trials and finally commercial production.
Our team of experienced chemists were tasked with the challenge of finding a new formulation to improve the stability of Oncopeptides drug product, as well as assist as it passed through to the clinical development stages.
To find out how we helped, read the full case study here: